Last week started off with a bang. First thing Monday morning, Pfizer and Allergan announced plans to merge in a record-setting $160 billion deal in the pharm space. Unfortunately for the companies, the deal added fuel to the fire in the ferocious battle over what many in Washington, DC, now refer to as "tax inversion"...
Last week started off with a bang. First thing Monday morning, Pfizer and Allergan announced plans to merge in a record-setting $160 billion deal in the pharm space. Unfortunately for the companies, the deal added fuel to the fire in the ferocious battle over what many in Washington, DC, now refer to as "tax inversion"...
Share this Article
Recommended